StockWatch
·
Medical Specialities
Quarterly ResultAug 5, 2026, 04:09 PM

Trupanion Authorizes $100M Buyback, $44M Dividend; Q2 Revenue $392.9M

AI Summary

Trupanion, Inc. announced its second quarter 2026 financial results, reporting an 11% increase in total revenue to $392.9 million. While net income decreased to $6.8 million from $9.4 million year-over-year, adjusted EBITDA improved to $19.8 million. The company also announced significant capital allocation news, including the approval of a $44 million extraordinary dividend and the authorization of a $100 million share repurchase program.

Key Highlights

  • Board authorized a $100M share repurchase program.
  • New York DFS approved a $44M extraordinary dividend.
  • Q2 2026 total revenue increased 11% to $392.9M.
  • Q2 2026 net income was $6.8M, or $0.16 per share.
  • Q2 2026 adjusted EBITDA rose to $19.8M from $16.6M.
  • Subscription business revenue grew 14% to $276.7M.
  • Subscription enrolled pets increased 5% to 1,124,548.
  • Operating cash flow was $21.0M and free cash flow $19.2M.